Physician profile
Jonathan Duong
NPI 1366484115
$1,552.86
in general payments reported to CMS, 2019-2025
10 companies · $34.90 in 2025
The $34.90 reported for 2025 was less than what a typical Vision Therapy provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $50.24 · 2021: $534 · 2022: $162 · 2023: $411 · 2025: $34.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $354.69 | 2019-2023 | Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $354.29 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $301.99 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $189.98 | 2023 | Infuse |
| Karyopharm Therapeutics INC. | $125.00 | 2023 | Xpovio |
| Kala Pharmaceuticals, INC. | $124.69 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $34.94 | 2019-2023 | Acuvue |
| Dompe US, INC. | $34.90 | 2025 | Oxervate |
| Allergan, INC. | $18.58 | 2022 | |
| Coopervision INC. | $13.80 | 2023 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.